Michael Heinrich

Professor

  • 32989 Citations
  • 78 h-Index
1985 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Michael Heinrich is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 15 Similar Profiles
Gastrointestinal Stromal Tumors Medicine & Life Sciences
Mutation Medicine & Life Sciences
Phosphotransferases Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Protein-Tyrosine Kinases Medicine & Life Sciences
Acute Myeloid Leukemia Medicine & Life Sciences
Exons Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1985 2019

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma

Van Herpen, C. M. L., Agarwala, S. S., Hauschild, A., Berking, C., Thaddeus Beck, J., Schadendorf, D., Jansen, R., Queirolo, P., Ascierto, P. A., Blank, C. U., Heinrich, M., Pal, R. R., Derti, A., Antona, V., Nauwelaerts, H., Zubel, A. & Dummer, R., Mar 1 2019, In : Oncotarget. 10, 19, p. 1850-1859 10 p.

Research output: Contribution to journalArticle

Melanoma
Biomarkers
Mitogen-Activated Protein Kinases
Mitogen-Activated Protein Kinase Kinases
Mutation

Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants

Eide, C. A., Zabriskie, M. S., Savage Stevens, S. L., Antelope, O., Vellore, N. A., Than, H., Schultz, A. R., Clair, P., Bowler, A. D., Pomicter, A. D., Yan, D., Senina, A. V., Qiang, W., Kelley, T. W., Szankasi, P., Heinrich, M. C., Tyner, J. W., Rea, D., Cayuela, J. M., Kim, D. W. & 4 others, Tognon, C. E., O'Hare, T., Druker, B. J. & Deininger, M. W., Oct 14 2019, In : Cancer Cell. 36, 4, p. 431-443.e5

Research output: Contribution to journalArticle

Protein-Tyrosine Kinases
Adenosine Triphosphate
ponatinib
1 Citation (Scopus)

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

Serrano, C., Mariño-Enríquez, A., Tao, D. L., Ketzer, J., Eilers, G., Zhu, M., Yu, C., Mannan, A. M., Rubin, B. P., Demetri, G. D., Raut, C. P., Presnell, A., McKinley, A., Heinrich, M., Czaplinski, J. T., Sicinska, E., Bauer, S., George, S. & Fletcher, J. A., Mar 19 2019, In : British Journal of Cancer. 120, 6, p. 612-620 9 p.

Research output: Contribution to journalArticle

Gastrointestinal Stromal Tumors
Protein-Tyrosine Kinases
Mutation
Clinical Trials
Growth

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours (British Journal of Cancer, (2019), 120, 6, (612-620), 10.1038/s41416-019-0389-6)

Serrano, C., Mariño-Enríquez, A., Tao, D. L., Ketzer, J., Eilers, G., Zhu, M., Yu, C., Mannan, A. M., Rubin, B. P., Demetri, G. D., Raut, C. P., Presnell, A., McKinley, A., Heinrich, M., Czaplinski, J. T., Sicinska, E., Bauer, S., George, S. & Fletcher, J. A., Jan 1 2019, In : British Journal of Cancer.

Research output: Contribution to journalComment/debate

Open Access
Gastrointestinal Stromal Tumors
Expert Testimony
Protein-Tyrosine Kinases
Mutation
Pharmaceutical Preparations

Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis

Berdeja, J. G., Heinrich, M., Dakhil, S. R., Goldberg, S. L., Wadleigh, M., Kuriakose, P., Cortes, J., Radich, J., Helton, B., Rizzieri, D., Paley, C., Dautaj, I. & Mauro, M. J., Jan 1 2019, In : Leukemia and Lymphoma.

Research output: Contribution to journalArticle

Open Access
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Polymerase Chain Reaction
Leukemia, Myeloid, Chronic Phase
Multicenter Studies
Safety